Background: Liver damage caused by hepatitis C virus (HCV) is the number one indication for liver transplantation in the United States and Europe. Patients with a detectable HCV level at time of transplant will universally develop a recurrent infection, which can lead to increased morbidity and mortality. Objective: To assess the sustained virologic response rate post end-of-treatment (SVR) in HCV-infected, post-liver transplant patients at the University of Washington Medical Center (UWMC) treated with ledipasvir-sofosbuvir (LDV/SOF). Methods: This retrospective, cohort study of HCVpositive, genotype 1 or 4 infected, post-liver transplant patients treated with LDV/SOF was conducted at a large academic medical center affiliated clinic. Patients treated with 12 weeks of LDV/SOF with or without ribavirin were included in the 12-week group, and patients treated with 24 weeks of LDV/SOF without ribavirin were included in the 24-week group. Results: Twenty-nine patients with recurrent HCV post-liver transplant receiving 12 weeks of LDV/SOF with or without ribavirin and 32 patients receiving 24 weeks of LDV/SOF alone were assessed. SVR was achieved by 100% (29/29) of patients in the 12-week group and 100% (32/32) of patients in the 24-week group. Conclusion: Post-liver transplant patients at UWMC treated with LDV/SOF for recurrent HCV achieved high rates of SVR.
Introduction
An estimated 3 to 4 million people in the United States are living with chronic hepatitis C virus (HCV) and many are currently undiagnosed. Untreated HCV can progress to liver disease and hepatocellular carcinoma. 1, 2 Liver damage caused by HCV is the number one indication for liver transplantation in the United States and Europe. Patients with a detectable HCV level at time of transplant will universally develop a recurrent HCV infection, which can lead to increased morbidity and mortality. [3] [4] [5] [6] Without treatment, 10% to 25% of post-liver transplant patients will develop HCV-related cirrhosis within 5 years. 5 Prior to the development of direct-acting antiviral (DAA) agents, HCV postliver transplant was treated with pegylated α-interferon and ribavirin. This regimen was poorly tolerated with a low rate of viral clearance ranging from 20% to 40%. 4 With the development of new DAAs, treating HCV is more tolerable for patients and the likelihood of achieving disease remission has increased. 3, 7, 8 These agents have demonstrated a similar rate of sustained virologic response (SVR) in post-liver transplant patients compared with nontransplant patients. 9 Additionally, DAA agents are ideal for post-liver transplant patients due to limited hepatic metabolism and minimal drug interactions with antirejection posttransplant medications. 10 Patients achieving SVR 12 weeks post end-of-treatment (SVR12) are considered to be cured of hepatitis C as virologic relapse after 12 weeks post end-of-treatment is rare. 1 Sofosbuvir, a nucleotide polymerase inhibitor, and ledipasvir, a HCV NS5A inhibitor, are available in a single, fixed dose oral tablet with US Food and Drug Administration (FDA) approval to treat HCV genotypes 1 and 4. 11 In the ION-1 study, previously untreated patients with HCV genotype 1 with and without cirrhosis achieved SVR12 of 97% or greater while taking this oral regimen. This trial demonstrates the benefit of ledipasvir-sofosbuvir (LDV/ SOF), but does not address the critical population of HCVpositive liver transplant patients. The SOLAR-1 trial assessed the efficacy of LDV/SOF with ribavirin in patients with HCV genotypes 1 and 4 infection and advanced liver disease. 3 One arm of this study specifically evaluated posttransplant LDV/SOF treatment in 229 liver transplant patients with varying degrees of liver damage. This phase II study demonstrated a SVR12 rate greater than 85% for all transplant patients except for those with Child-TurcottePugh (CTP) Class C disease. The American Association for the Study of Liver Disease (AASLD) Hepatitis C guidelines currently recommend LDV/SOF with or without ribavirin for treatment of HCV-positive, genotype 1 or 4, liver transplant patients. 1 While the results from the SOLAR-1 trial are promising, additional information is needed to describe the response rate in the real-world liver transplant population. The University of Washington Medical Center (UWMC) Hepatology Clinic commonly treats HCV patients including HCV-positive post-liver transplant patients. This puts UWMC in a unique position to assess the real-world virologic response rate in liver transplant patients treated with LDV/SOF.
Study Setting and Clinical Practice
The UWMC is a 450-bed, tertiary care, academic teaching institution with affiliated clinics. In 2015, UWMC performed 90 liver transplants. The Hepatology Clinic provides care to patients with HCV, including diagnosis and treatment of HCV-positive, post-liver transplant patients. Physicians, midlevel practitioners, and a specialty clinical pharmacist comprise the health care team that manages the patients' medication regimen and laboratory findings.
HCV treatment is based on guideline recommendations, patient-specific factors, physician preference, and patient cost consideration. Ledipasvir-sofosbuvir is an FDA approved and guideline-recommended treatment for postliver transplant patients. 1, 12 All post-liver transplant patients with genotypes 1 and 4 are candidates for LDV/SOF treatment with or without ribavirin. First-line recommendation is to treat patients with a 12-week course of once daily LDV/SOF (90 mg/400 mg) plus weight-based ribavirin in 2 divided doses (1000 mg in patients with body weight <75 kg and 1200 mg in patients with body weight ≥75 kg). Patients with a past history of intolerance to ribavirin or patients considered ineligible for ribavirin treatment (baseline low hemoglobin, men with a pregnant partner, and patients with renal insufficiency) may complete a 24-week course of daily, fixed-dose LDV/SOF alone. 13 Of note, physicians at UWMC initiated use of LDV/SOF in post-liver transplant HCV-infected patients prior to FDA approved use of this regimen. For this reason, some patients evaluated in this study were treated with 12 weeks of LDV/SOF monotherapy based on the ION trials and non-liver transplant labeling. Additional cost-related factors may influence the choice of agent such as insurer preference and availability of copay assistance programs. Due to the high cost of this regimen, patients may undergo a prior-authorization process to gain access to LDV/SOF. A 2014 retrospective review indicated one fourth of patients are denied initial coverage for LDV/SOF but the majority of patients are later approved through an appeal. 14 After the health care team decides on the course of therapy, effectiveness is assessed by measuring serum HCV RNA levels. The recommended time-points for HCV RNA monitoring at UWMC are at baseline, 4 weeks, 12 weeks, 24 weeks (if taking a 24-week regimen), 12 weeks post endof-treatment, and 24 weeks post end-of-treatment. If patients achieve SVR12 they are considered to have eradicated HCV and SVR24 is assessed to further confirm a patient has not had a viral relapse. 1 Monitoring at UWMC occurs more frequently than currently recommended in AASLD guidelines, which recommend monitoring at 4 weeks of therapy and 12 weeks after completion of therapy.
Materials and Methods

Patients and Group Assignment
This retrospective, cohort study was conducted at the UWMC Hepatology Clinic and was approved by the University of Washington Institutional Review Board, Human Subjects Division, with waived consent. All HCV, post-liver transplant patients starting treatment with LDV/ SOF between October 2014 and October 2015 were assessed for inclusion. Exclusion criteria consisted of treatment with agents other than LDV/SOF, co-infection with HIV or hepatitis B, age ≥85 years old or <18 years old, starting treatment before transplantation, and not having a 12-week or 24-week post end-of-treatment HCV RNA level drawn. Patients were included in the 12-week treatment group if they received treatment with LDV/SOF for a 12-week duration with or without weight-based ribavirin and patients who received LDV/SOF without ribavirin for 24 weeks were included in the 24-week group.
Data Collection and Study Outcomes
Eligible patients were retrospectively identified via the UWMC MAX database, a centralized electronic database used within the Hepatology Clinic. In addition, UWMC utilizes an outpatient electronic health record (EPIC). Data were electronically extracted from MAX records and via manual chart reviews of the electronic health record for all patients.
Data were collected between October 1, 2015, and July 30, 2016, and variables included demographic information such as age, weight, height, gender, baseline laboratory values, previous treatment regimens, stage of liver disease, and time since transplantation. Fibrosis stage was determined by liver biopsy or noninvasive testing. Previous treatment information is documented in the MAX database for every patient, and these data were electronically extracted. Previous treatment was documented as "yes" or "no." If "yes," previous treatment medications and treatment response were documented if known. Previous treatment response was recorded as "nonresponder," "relapse," and "unknown." Treatment-specific data included treatment duration and ribavirin dose. Additional extracted data included HCV RNA level prior to start of treatment, at 4 weeks, 12 weeks, 24 weeks (if taking a 24-week regimen), 12 weeks post end-of-treatment, and 24 weeks post end-of-treatment. HCV RNA levels were collected at UWMC laboratories and quantitatively measured using HCV RNA real-time polymerase chain reaction. Descriptive statistics were used to assess baseline demographics and study outcomes.
The primary endpoint was SVR rate within the 12-week group and 24-week group. Patients were considered to have achieved SVR if serum HCV RNA levels were <15 IU/mL at 12 weeks post end-of-treatment (SVR12) or at 24 weeks post end-of-treatment (SVR24). If a patient had both 12-week and 24-week post end-of-treatment levels drawn both levels were required to be <15 IU/mL.
Results
Baseline Demographics and Outcomes
A total of 82 post-liver transplant patients were identified as starting treatment for chronic HCV with LDV/SOF at UWMC between October 2014 and October 2015. A total of 21 patients were excluded, leaving 61 patients for analysis ( Figure 1) . Twenty-nine patients were included in the 12-week group and 32 patients were included in the 24-week group. At baseline, in the 12-week group and 24-week group median age was 61 and 64 years, the majority were male (75.9%, 87.5%), the majority had HCV genotype 1a infection (82.8%, 75%), over half were previously treated (65.5%, 62.5%), and median time since transplant was 3.5 years and 6.5 years, respectively. Fibrosis stage ranged from no fibrosis (31%, 31.3%) to stage 3 fibrosis (6.9%, 6.3%) in the 12-week and 24-week groups, respectively. Patients with cirrhosis were also present in both groups. In the 12-week group one patient (3.4%) had compensated cirrhosis and no patients had decompensated cirrhosis. In the 24-week group 5 patients (15.6%) had compensated cirrhosis and 2 patients (6.3%) had decompensated cirrhosis ( Table 1) .
The primary outcome of SVR (either SVR12 or SVR24) was achieved by 100% (29/29) of patients in the 12-week group and by 100% (32/32) of patients in the 24-week group (Table 2) . There was no difference in response rate observed between patients who had previously received treatment and treatment naïve patients, as well as no difference in response rate observed between patients with and without fibrosis or cirrhosis, as all patients achieved SVR.
Discussion
This small, retrospective, cohort study demonstrates high rates of SVR can be achieved in post-liver transplant patients treated with LDV/SOF with or without ribavirin. These results provide additional information about the expected HCV cure rates in the real-world setting and may be used to inform patients about their expected treatment results. Due to lack of randomization and observational nature, this study has high external validity and provides a real-world comparison for other treatment centers to evaluate their HCV outcomes. Safety and tolerability were not assessed, as the focus of this study was to assess realworld SVR outcomes. Due to all patients within both groups completing the course of therapy, a favorable safety and tolerability profile is assumed.
The SOLAR-1 trial was the first randomized controlled trial to assess the use of LDV/SOF with ribavirin for 12 weeks in HCV-positive post-liver transplant patients. SVR12 rates achieved varied from 96% for patients with no cirrhosis or CTP Class A disease, to 60% in patients with CTP Class C disease. Real-world populations may not always achieve the same level of results as randomized clinical trials. This is described as the "efficacy-effectiveness gap" and may be attributed to the strict inclusion/ exclusion criteria used for clinical trials and lack of external validity. 15 While it is challenging to draw a true comparison, SVR rates from the 12-week group in the present study were high and do not appear to be different from rates achieved in the SOLAR-1 trial. Patients evaluated at UWMC in the 12-week group may have been a healthier population compared to those assessed in the SOLAR-1 trial as there were no patients with decompensated cirrhosis, while 26% of patients in the SOLAR-1 trial had this There are several limitations to this study. First of all, patients were retrospectively assessed and not randomized or blinded, decreasing internal validity. Next, treatment regimens were chosen based on physician clinical judgment and therefore selection bias is of concern. Last, there was variability in the treatment regimen of patients in the 12-week group. Nine patients (31%) were treated with LDV/SOF alone for 12 weeks, as opposed to LDV/SOF with weightbased ribavirin. These patients were included in the 12-week treatment group, decreasing internal validity.
Conclusion
Overall, patients treated with LDV/SOF for 12 and 24 weeks at UWMC achieved high rates of SVR. The treatment team, increased level of HCV monitoring, and the frequency of visits at UWMC may be potential reasons why the assessed cohorts were able to achieve these results. A multidisciplinary team, with a specialty clinical pharmacist, monitors the treatment of HCV patients at clinic visits and through frequent laboratory monitoring. Prior to initiating therapy, the regimen and patient are thoroughly screened by the clinical pharmacist and an in-person visit with the clinical pharmacist occurs to provide patient education, discuss treatment expectations, adverse effects, and monitoring. For follow-up appointments patients present to clinic in person or by phone, which can occur as often as monthly, and have HCV RNA monitoring completed at baseline, 4 weeks, 12 weeks, 24 weeks (if taking a 24-week regimen), 12 weeks post end-of-treatment, and 24 weeks post end-oftreatment. Additionally, patients treated with ribavirin follow-up at 2 weeks, due to the need to assess complete blood count. At every visit adherence, adverse effects, and drug interactions are reviewed. The frequency and comprehensiveness of the visits may play a role in helping patients achieve SVR.
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